RhumbLine Advisers’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-57,744
| Closed | -$101K | – | 4245 |
|
|
2025
Q1 | $101K | Sell |
57,744
-1,787
| -3% | -$2.36K | ﹤0.01% | 3388 |
|
|
2024
Q4 | $94.1K | Sell |
59,531
-14,964
| -20% | -$23K | ﹤0.01% | 3493 |
|
|
2024
Q3 | $117K | Sell |
74,495
-1,977
| -3% | -$3.27K | ﹤0.01% | 3457 |
|
|
2024
Q2 | $136K | Buy |
+76,472
| New | +$177K | ﹤0.01% | 3407 |
|
|
2017
Q2 | – | Sell |
-463
| Closed | -$92K | – | 2949 |
|
|
2017
Q1 | $92K | Buy |
463
+133
| +40% | +$25.3K | ﹤0.01% | 2783 |
|
|
2016
Q4 | $89K | Buy |
330
+26
| +9% | +$8.45K | ﹤0.01% | 2800 |
|
|
2016
Q3 | $120K | Buy |
304
+6
| +2% | +$2.47K | ﹤0.01% | 2789 |
|
|
2016
Q2 | $103K | Buy |
298
+73
| +32% | +$52.3K | ﹤0.01% | 2911 |
|
|
2016
Q1 | $187K | Buy |
225
+1
| +0.4% | +$796 | ﹤0.01% | 2754 |
|
|
2015
Q4 | $234K | Buy |
224
+13
| +6% | +$13K | ﹤0.01% | 2712 |
|
|
2015
Q3 | $165K | Buy |
211
+9
| +4% | +$9.24K | ﹤0.01% | 2856 |
|
|
2015
Q2 | $266K | Buy |
202
+81
| +67% | +$131K | ﹤0.01% | 2738 |
|
|
2015
Q1 | $247K | Buy |
121
+34
| +39% | +$73.9K | ﹤0.01% | 2720 |
|
|
2014
Q4 | $168K | Sell |
87
-4
| -4% | -$7.11K | ﹤0.01% | 2864 |
|
|
2014
Q3 | $75K | Hold |
91
| – | – | ﹤0.01% | 2948 |
|
|
2014
Q2 | $88K | Buy |
+91
| New | +$78K | ﹤0.01% | 2977 |
|
Other funds holding RGLS
RhumbLine Advisers's RGLS Position: Q2 2025 in Review
RhumbLine Advisers sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 57,744 shares — an estimated $101K sold.
RhumbLine Advisers first reported a position in RGLS in Q2 2014 and held it in 16 quarters. The position peaked at $266K in Q2 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- RhumbLine Advisers reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- RhumbLine Advisers sold 57,744 Regulus Therapeutics shares in Q2 2025, an estimated $101K.
- RhumbLine Advisers first reported a position in Regulus Therapeutics in Q2 2014 and held it in 16 quarters.
- RhumbLine Advisers's Regulus Therapeutics position peaked at $266K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.